Evidence map›Paper›PMID 31651343›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

Correction to: Cell communication and signaling: how to turn bad language into positive one.

Claudia Chiodoni, Maria Teresa Di Martino, Francesca Zazzeroni, Michele Caraglia, Massimo Donadelli, Stefania Meschini, Carlo Leonetti, Katia Scotlandi

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Claudia ChiodoniMolecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. claudia.chiodoni@istitutotumori.mi.it.
Maria Teresa Di MartinoDepartment of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.
Francesca ZazzeroniDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Michele CaragliaDepartment of Biochemistry, Biophysics and General Pathology, University of Campania "L. Vanvitelli", Naples, Italy.
Massimo DonadelliDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry, University of Verona, Verona, Italy.
Stefania MeschiniNational Center for Drug Research and Evaluation, National Institute of Health, Rome, Italy.
Carlo LeonettiUOSD SAFU, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Katia ScotlandiExperimental Oncology Lab, CRS Development of Biomolecular Therapies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. katia.scotlandi@ior.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the original publication of this article, [1] the affiliation for Katia Scotlandi needs to be revised, because the author prefers using its Italian name: Experimental Oncology Lab, Experimental Oncology Lab, CRS Development of Biomolecular Therapies, IRCCS Istituto Ortopedico Rizzoli. We apologize for any confusion this may have caused.

Identifiers

PMID31651343
PMCPMC6814022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.